Your browser doesn't support javascript.
loading
Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine.
Mahon, Ronan; Vo, Pamela; Pannagl, Katharina; Tiwari, Santosh; Heemstra, Harald; Ferraris, Matias; Zhao, Jing; Betts, Keith A; Proot, Pascal.
Affiliation
  • Mahon R; Novartis Ireland Limited, Dublin, Ireland.
  • Vo P; Novartis Pharma AG, Basel, Switzerland.
  • Pannagl K; Novartis Pharmaceuticals UK Limited, London, UK.
  • Tiwari S; Novartis Healthcare Private Limited, Hyderabad, India.
  • Heemstra H; Novartis Pharma AG, Basel, Switzerland.
  • Ferraris M; Novartis Pharma AG, Basel, Switzerland.
  • Zhao J; Analysis Group, Inc, Los Angeles, CA, USA.
  • Betts KA; Analysis Group, Inc, Los Angeles, CA, USA.
  • Proot P; Ghent University Hospital, Ghent, Belgium.
Curr Med Res Opin ; 39(1): 105-112, 2023 01.
Article in En | MEDLINE | ID: mdl-36189948
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Botulinum Toxins, Type A / Migraine Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Curr Med Res Opin Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Botulinum Toxins, Type A / Migraine Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Curr Med Res Opin Year: 2023 Document type: Article Affiliation country: Country of publication: